{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:17:03Z","timestamp":1770135423387,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/jcp.0b013e3181694f5a","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T07:01:06Z","timestamp":1205218866000},"page":"S12-S19","source":"Crossref","is-referenced-by-count":82,"title":["Safety Profile of Iloperidone"],"prefix":"10.1097","volume":"28","author":[{"given":"Peter J.","family":"Weiden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihael H.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt D.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.7.13.1739","article-title":"A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.","volume":"7","author":"Luft","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov Disord"},{"issue":"suppl 27","key":"R3-3-20210128","first-page":"3","article-title":"Metabolic disturbances associated with antipsychotic use.","volume":"62","author":"Newcomer","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"suppl 4","key":"R4-3-20210128","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk.","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0306-4530(02)00111-7","article-title":"Atypical antipsychotics in the EPS-vulnerable patient.","volume":"28","author":"Friedman","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0024-3205(03)00419-3","article-title":"Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.","volume":"73","author":"Kalkman","year":"2003","journal-title":"Life Sci"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","article-title":"Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders.","volume":"25","author":"Kalkman","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.","volume":"28","author":"Cutler","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS).","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease.","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease.","volume":"8","author":"Fridericia","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","article-title":"Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.","volume":"28","author":"Kane","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","article-title":"Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.","volume":"65","author":"Misra","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14737175.7.7.829","article-title":"Cardiovascular effects of antipsychotics.","volume":"7","author":"Michelsen","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications.","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3181694f5a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T23:41:32Z","timestamp":1684280492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200804001-00003"}},"subtitle":["A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials"],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181694f5a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}